Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Todd W. Siegel is active.

Publication


Featured researches published by Todd W. Siegel.


European Journal of Medicinal Chemistry | 1992

Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids

Hr Howard; Reinhard Sarges; Todd W. Siegel; Thomas A. Beyer

Abstract Potent in vitro inhibition of the enzyme aldose reductase (AR) was observed with several members of a series of 3-alkylated 2(1 H )-benzimidazolone-1-acetic acids, as well as with analogs from a structurally-related series of oxindole-1-acetic acids with 3-alkyl or 3-alkylidene substituents. Intrinsic activity against AR was, in general, greatest in compounds from the second series, especially with analogs which contain alkylidene side chains, with typical IC 50 values of ≤ 1 μM. However, in a streptozotocin-diabetic rat model, the best compounds from either series failed to prevent sorbitol accumulation in lens or sciatic nerve to the degree observed with AR inhibitors such as ponalrestat or zopolrestat.


Life Sciences | 1991

The role of polyols in cerebral cell volume regulation in hypernatremic and hyponatremic states

Howard Trachtman; Stephen Futterweit; Ellen Hammer; Todd W. Siegel; Peter J. Oates

To clarify the role of the sugar polyols, sorbitol and myo-inositol, in cerebral cell volume regulation, we studied the effect of sorbinil, an inhibitor of aldose and aldehyde reductase, on the size of the cerebral water compartments in rats with hypernatremia, hyponatremia and normonatremia. Experimental animals were pretreated with sorbinil, while comparison rats received the drug vehicle. Rats were made hypernatremic for 96 h by water deprivation and injections of hypertonic saline, while hyponatremia was provoked over 48 h by daily administration of 5% dextrose in water and vasopressin. Sorbinil treatment was continued throughout the hyper- and hyponatremic periods. The severity of hypernatremia and hyponatremia was similar in sorbinil-treated and corresponding vehicle-treated rats. Brain electrolyte content and the size of the cerebral intracellular water compartment were comparable in sorbinil-treated rats vs. controls under hypernatremic and hyponatremic conditions. Sorbinil reduced the cerebral sorbitol content by approximately 50%, irrespective of the serum Na+ concentration. In contrast, sorbinil had no effect on brain myo-inositol content which rose by 114% during chronic hypernatremia (P less than 0.0001). Cerebral levels of myo-inositol did not decline in hyponatremic rats. We conclude that (1) sorbitol is not an essential cerebral osmolyte; and (2) myo-inositol is involved in the maintenance of brain cell volume during severe hypernatremia but not under hyponatremic conditions.


Bioorganic & Medicinal Chemistry Letters | 2001

Small molecule somatostatin receptor subtype-2 antagonists.

Bruce A. Hay; Bridget Mccarthy Cole; Frank M. DiCapua; Glen W. Kirk; Marianne C. Murray; Rona A. Nardone; Dennis J. Pelletier; Anthony Paul Ricketts; Alan Robertson; Todd W. Siegel

The first potent small molecule sst2 antagonists are reported. Altering known sst2 agonist molecules yielded compounds with high sst2 binding affinity and full antagonist activity. Compound 7a, for example, displaced somatostatin binding to the sst2 receptor with an IC(50)=2.9 nM and antagonized somatostatin action with an IC(50)=29nM.


Journal of Medicinal Chemistry | 1991

Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-[[5-(trifluoromethyl)-2-benzothiazolyl] methyl]-1-phthalazineacetic acid (zopolrestat) and congeners.

Banavara L. Mylari; Eric R. Larson; Thomas A. Beyer; William James Zembrowski; Charles E. Aldinger; Michael F. Dee; Todd W. Siegel; David H. Singleton


Archive | 1993

Substituted pyrimidines for control of diabetic complications

Banavara L. Mylari; Peter J. Oates; Todd W. Siegel; William James Zembrowski


Journal of Medicinal Chemistry | 1991

A HIGHLY SPECIFIC ALDOSE REDUCTASE INHIBITOR, ETHYL 1-BENZYL-3-HYDROXY-2(5H)-OXOPYRROLE-4-CARBOXYLATE, AND ITS CONGENERS

Banavara L. Mylari; Thomas A. Beyer; Todd W. Siegel


Journal of Medicinal Chemistry | 1992

Potent, orally active aldose reductase inhibitors related to zopolrestat: surrogates for benzothiazole side chain.

Banavara L. Mylari; Thomas A. Beyer; Pamela J. Scott; Charles E. Aldinger; Michael F. Dee; Todd W. Siegel; William James Zembrowski


Journal of Medicinal Chemistry | 1992

Orally active aldose reductase inhibitors : indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives

Banavara L. Mylari; William James Zembrowski; Thomas A. Beyer; Charles E. Aldinger; Todd W. Siegel


Journal of Medicinal Chemistry | 1992

Hydantoin bioisosteres. In vivo active spiro hydroxy acetic acid aldose reductase inhibitors

Christopher A. Lipinski; Charles E. Aldinger; Thomas A. Beyer; Jon Bordner; Douglas F. Burdi; Donald L. Bussolotti; Philip B. Inskeep; Todd W. Siegel


Journal of Medicinal Chemistry | 1990

Spiro hydantoin aldose reductase inhibitors derived from 8-aza-4-chromanones.

Reinhard Sarges; Steven Wayne Goldstein; Willard Mckowan Welch; Archie C. Swindell; Todd W. Siegel; Thomas A. Beyer

Researchain Logo
Decentralizing Knowledge